DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

8 Drugs in Development

8 Drugs in Development

INTERMEDIATES

1 Intermediates Suppliers

1 Intermediates Suppliers

DIGITAL CONTENT

4 NEWS #PharmaBuzz

media
4 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 755038-65-4, Bi 6727, Volasertib (bi 6727), Bi-6727, Bi6727 (volasertib), Volasertib [usan]

Molecular Formula

C₃₄H₅₀N₈O₃

Molecular Weight

618.8 g/mol

InChI Key

SXNJFOWDRLKDSF-XKHVUIRMSA-N

FDA UNII

6EM57086EA

Volasertib is a dihydropteridinone Polo-like kinase 1 (Plk1) inhibitor with potential antineoplastic activity. Volasertib selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner.

1 2D Structure

Volasertib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N-[4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl]-4-[[(7R)-7-ethyl-5-methyl-6-oxo-8-propan-2-yl-7H-pteridin-2-yl]amino]-3-methoxybenzamide

2.1.2 InChI

InChI=1S/C34H50N8O3/c1-6-28-33(44)39(4)29-20-35-34(38-31(29)42(28)22(2)3)37-27-14-9-24(19-30(27)45-5)32(43)36-25-10-12-26(13-11-25)41-17-15-40(16-18-41)21-23-7-8-23/h9,14,19-20,22-23,25-26,28H,6-8,10-13,15-18,21H2,1-5H3,(H,36,43)(H,35,37,38)/t25?,26?,28-/m1/s1

2.1.3 InChI Key

SXNJFOWDRLKDSF-XKHVUIRMSA-N

2.1.4 Canonical SMILES

CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C

2.1.5 Isomeric SMILES

CC[C@@H]1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C

2.2 Other Identifiers

2.2.1 UNII

6EM57086EA

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Bi 6727

2. Bi-6727

2.3.2 Depositor-Supplied Synonyms

1. 755038-65-4

2. Bi 6727

3. Volasertib (bi 6727)

4. Bi-6727

5. Bi6727 (volasertib)

6. Volasertib [usan]

7. 6em57086ea

8. Volasertib (usan)

9. Bi6727

10. Bi6727(volasertib)

11. Benzamide, N-(trans-4-(4-(cyclopropylmethyl)-1-piperazinyl)cyclohexyl)-4-(((7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl)amino)-3-methoxy-

12. N-((1s,4s)-4-(4-(cyclopropylmethyl)piperazin-1-yl)cyclohexyl)-4-(((r)-7-ethyl-8-isopropyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-methoxybenzamide

13. N-(trans-4-(4-(cyclopropylmethyl)piperazin-1-yl)cyclohexyl)-4-(((r)-7-ethyl-8-isopropyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-methoxybenzamide

14. N-{trans-4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl}-4-{[(7r)-7-ethyl-5-methyl-8-(1-methylethyl)-6-oxo-5,6,7,8-tetrahydropteridin-2-yl]amino}-3-methoxybenzamide

15. Volasertib [usan:inn]

16. Unii-6em57086ea

17. Ibi

18. N-(trans-4-(4-(cyclopropylmethyl)piperazin-1-yl)cyclohexyl)-4-(((7r)-7-ethyl-5-methyl-8-(1-methylethyl)-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-methoxybenzamide

19. Bi6727,volasertib

20. Volasertib(bi6727)

21. Volasertib [inn]

22. Bi6727 - Volasertib

23. Volasertib [who-dd]

24. Mls006011195

25. Schembl738946

26. Gtpl7947

27. Schembl2169101

28. Schembl9888052

29. Chembl1233528

30. Chembl4284151

31. Schembl21916558

32. Bcpp000341

33. Dtxsid801099395

34. Dtxsid901025694

35. Bcp02405

36. Ex-a1364

37. Bdbm50402023

38. Mfcd20926414

39. Nsc757149

40. Nsc800965

41. S2235

42. Zinc39716290

43. Akos030257530

44. Zinc100071772

45. Zinc248087828

46. Bcp9000403

47. Ccg-264952

48. Cs-0274

49. Db12062

50. Nsc-757149

51. Nsc-800965

52. Ncgc00263087-01

53. Ncgc00263087-02

54. Ncgc00263087-03

55. Ncgc00263087-12

56. Ncgc00263087-15

57. Ncgc00485964-01

58. Ac-32844

59. As-16996

60. Hy-12137

61. N-[4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl]-4-[[(7r)-7-ethyl-5-methyl-6-oxo-8-propan-2-yl-7h-pteridin-2-yl]amino]-3-methoxybenzamide

62. Smr004702964

63. Sw218140-2

64. D10182

65. Sr-03000003275

66. Q7939986

67. Sr-03000003275-1

68. 755038-54-1

69. N-((trans)-4-(4-(cyclopropylmethyl)piperazin-1-yl)cyclohexyl)-4-((r)-7-ethyl-8-isopropyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-ylamino)-3-methoxybenzamide

70. N-[cis-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxybenzamide

71. N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxybenzamide

2.4 Create Date

2006-10-25

3 Chemical and Physical Properties

Molecular Formula	C₃₄H₅₀N₈O₃
Molecular Weight	618.8 g/mol
XLogP3	4.6
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	9
Rotatable Bond Count	10
Exact Mass	618.40058749 g/mol
Monoisotopic Mass	618.40058749 g/mol
Topological Polar Surface Area	106 Å²
Heavy Atom Count	45
Formal Charge	0
Complexity	996
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1